News

Epigral Limited will hold a meeting of its Board of Directors on November 2, 2026, to consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2026, along with the Limited Review Report from the statutory auditors.

Epigral Limited informed the National Stock Exchange of India Limited and BSE Limited that it received a confirmation certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, for the quarter ended September 30, 2026, pertaining to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Epigral Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for equity shares will be closed for insiders, directors, promoters, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the un-audited financial results for the second quarter and half year ended September 30, 2026.

Net profit of Epigral declined 37.93% to Rs 99.74 crore in the quarter ended June 2026 as against Rs 160.69 crore during the previous quarter ended June 2025. Sales rose 16.29% to Rs 705.36 crore in the quarter ended June 2026 as against Rs 606.54 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales705.36606.54 16 OPM %25.4126.94 - PBDT176.64148.55 19 PBT133.74107.01 25 NP99.74160.69 -38 Powered by Capital Market - Live News

Epigral announced that as part of its strategic growth and expansion initiatives, it proposes to establish a new manufacturing facility for Epoxy Resin & Formulations and Multi-Purpose Plant (MPP) at its existing facility at Dahej, Gujarat.